Table 3.

Hazard ratios (HR) and 95% confidence intervals (CI) of primary, secondary, and other outcomes by randomized assignment to vitamin D^a

Endpoint	Vitamin D (N = 12,927)	Placebo (N = 12,944)	HR	95% CI
	no. of participants w/event
Cardiovascular disease (CVD), primary and secondary outcomes
Major CVD eventb,c	396	409	0.97	0.85–1.12
Expanded CVD eventd	536	558	0.96	0.86–1.08
Total myocardial infarction	169	176	0.96	0.78–1.19
Total stroke	141	149	0.95	0.76–1.20
Cardiovascular mortality	152	138	1.11	0.88–1.40
Other vascular outcomese
Percutaneous coronary intervention (PCI)	182	188	0.97	0.79–1.19
Coronary artery bypass graft (CABG)	73	98	0.75	0.55–1.01
Fatal MI	24	15	1.60	0.84–3.06
Fatal stroke	19	23	0.84	0.46–1.54
Total invasive cancerb	793	824	0.96	0.88–1.06
Cancer mortality	154	187	0.83	0.67–1.02
All-cause mortality	485	493	0.99	0.87–1.12
Excluding the first two years of follow-up:
Major CVD event	274	296	0.93	0.79–1.09
Total invasive cancer	490	522	0.94	0.83–1.06
Cancer mortality	112	149	0.75	0.59–0.96
All-cause mortality	368	384	0.96	0.84–1.11

^aAnalyses were from Cox regression models controlling for age, sex, and n-3 fatty acid randomization group. Analyses were not adjusted for multiple comparisons.

^bPrimary outcome.

^cA composite of myocardial infarction, stroke, and cardiovascular mortality.

^dA composite of major cardiovascular events plus coronary revascularization (CABG + PCI).

^eNot prespecified as primary or secondary outcomes.